301281 科源制药
已收盘 04-30 15:00:00
资讯
新帖
简况
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
股市必读：科源制药一季报 - 第一季度单季净利润同比增长30.27%
证券之星 · 04-27
股市必读：科源制药一季报 - 第一季度单季净利润同比增长30.27%
科源制药(301281)3月31日股东户数0.89万户，较上期减少16.39%
证券之星 · 04-24
科源制药(301281)3月31日股东户数0.89万户，较上期减少16.39%
图解科源制药一季报：第一季度单季净利润同比增长30.27%
证券之星 · 04-24
图解科源制药一季报：第一季度单季净利润同比增长30.27%
股市必读：科源制药年报 - 第四季度单季净利润同比下降171.84%
证券之星 · 04-17
股市必读：科源制药年报 - 第四季度单季净利润同比下降171.84%
科源制药（301281）披露使用部分闲置募集资金及自有资金进行现金管理的公告，4月15日股价上涨2.77%
证券之星 · 04-15
科源制药（301281）披露使用部分闲置募集资金及自有资金进行现金管理的公告，4月15日股价上涨2.77%
科源制药(301281.SZ)发布2025年度业绩，归母净利润1655.3万元，下降72.62%
智通财经 · 04-15
科源制药(301281.SZ)发布2025年度业绩，归母净利润1655.3万元，下降72.62%
科源制药：力诺制药与江苏赛邦药业有限公司诉讼案件目前已进入二审阶段
证券之星 · 04-13
科源制药：力诺制药与江苏赛邦药业有限公司诉讼案件目前已进入二审阶段
科源制药（301281）210万股限售股将于4月7日解禁，占总股本1.94%
证券之星 · 04-07
科源制药（301281）210万股限售股将于4月7日解禁，占总股本1.94%
科源制药（301281）披露首次公开发行前部分限售股解禁并上市流通提示性公告，4月3日股价下跌5.13%
证券之星 · 04-03
科源制药（301281）披露首次公开发行前部分限售股解禁并上市流通提示性公告，4月3日股价下跌5.13%
股市必读：科源制药（301281）3月26日收盘跌10.15%，主力净流出1995.85万元
证券之星 · 03-27
股市必读：科源制药（301281）3月26日收盘跌10.15%，主力净流出1995.85万元
股市必读：科源制药（301281）3月23日收盘跌10.32%，主力净流出284.85万元
证券之星 · 03-24
股市必读：科源制药（301281）3月23日收盘跌10.32%，主力净流出284.85万元
科源制药（301281）披露控股股东部分股份解除质押及再质押公告，3月16日股价上涨1.69%
证券之星 · 03-16
科源制药（301281）披露控股股东部分股份解除质押及再质押公告，3月16日股价上涨1.69%
科源制药股东拟减持不超过3%股份，减持计划为期三个月
美股速递 · 03-16
科源制药股东拟减持不超过3%股份，减持计划为期三个月
科源制药最新公告：股东济南鼎佑拟减持不超3.00%股份
证券之星 · 03-16
科源制药最新公告：股东济南鼎佑拟减持不超3.00%股份
科源制药（301281）披露全资子公司银行账户部分金额解除冻结的公告，3月13日股价上涨3.46%
证券之星 · 03-13
科源制药（301281）披露全资子公司银行账户部分金额解除冻结的公告，3月13日股价上涨3.46%
科源制药业绩“变脸”再陷困局：诉讼赔偿、战略摇摆与资金链隐忧并存
新浪证券 · 03-06
科源制药业绩“变脸”再陷困局：诉讼赔偿、战略摇摆与资金链隐忧并存
科源制药最新公告：预计2025年净利润同比减少70%-80%
证券之星 · 02-24
科源制药最新公告：预计2025年净利润同比减少70%-80%
2月24日科源制药发布公告，股东减持28.27万股
证券之星 · 02-24
2月24日科源制药发布公告，股东减持28.27万股
股市必读：科源制药（301281）预计2025年全年归属净利润盈利2720.19万元至3929.16万元
证券之星 · 02-02
股市必读：科源制药（301281）预计2025年全年归属净利润盈利2720.19万元至3929.16万元
加载更多
公司概况
公司名称：
山东科源制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-04-04
主营业务：
山东科源制药股份有限公司的主营业务是化学原料药及其制剂产品的研发、生产和销售。公司的主要产品是格列齐特、盐酸二甲双胍、盐酸罗哌卡因、单硝酸异山梨酯、单硝酸异山梨酯片、单硝酸异山梨酯缓释片、盐酸氟西汀分散片、化工中间体产品。
发行价格：
44.18
{"stockData":{"symbol":"301281","market":"SZ","secType":"STK","nameCN":"科源制药","latestPrice":37.69,"timestamp":1777532595000,"preClose":37.89,"halted":0,"volume":2150723,"delay":0,"changeRate":-0.0053,"floatShares":70952000,"shares":108000000,"eps":0.2174,"marketStatus":"已收盘","change":-0.2,"latestTime":"04-30 15:00:00","open":38,"high":38.12,"low":37.37,"amount":81080500,"amplitude":0.0198,"askPrice":37.7,"askSize":3,"bidPrice":37.69,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.2174,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":37.89,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":41.68,"lowLimit":34.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":108290000,"isCdr":false,"pbRate":2.95,"roa":"--","peRate":173.367065,"roe":"2.19%","epsLYR":0.15,"committee":0.246753,"marketValue":4081000000,"turnoverRate":0.0303,"status":1,"floatMarketCap":2674000000},"requestUrl":"/m/hq/s/301281","defaultTab":"news","newsList":[{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300723","BK0188","LU2328871848.SGD","BK0028","BK0183","BK0209","LU1969619763.USD","BK0191","BK0175","BK1161","BK1574","BK0132","BK0187","BK0071","BK0196","000950","688117","06978","002550","600216","BK0216","301281","000963","BK0239","688621","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331491","title":"股市必读：科源制药一季报 - 第一季度单季净利润同比增长30.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331491","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630331491?lang=zh_cn&edition=full","pubTime":"2026-04-27 06:22","pubTimestamp":1777242131,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，科源制药报收于37.42元，下跌4.52%，换手率10.4%，成交量7.38万手，成交额2.76亿元。股本股东变化股东户数变动近日科源制药披露，截至2026年3月31日公司股东户数为8878.0户，较12月31日减少1740.0户，减幅为16.39%。业绩披露要点财务报告科源制药2026年一季报显示，一季度公司主营收入1.61亿元，同比上升45.05%；归母净利润3007.34万元，同比上升30.27%；扣非净利润2842.69万元，同比上升50.17%；负债率22.19%，投资收益60.0万元，财务费用19.02万元，毛利率57.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700006627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629814055","title":"科源制药(301281)3月31日股东户数0.89万户，较上期减少16.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629814055","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629814055?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:43","pubTimestamp":1777023832,"startTime":"0","endTime":"0","summary":"证券之星消息，近日科源制药披露，截至2026年3月31日公司股东户数为8878.0户，较12月31日减少1740.0户，减幅为16.39%。在化学制药行业个股中，科源制药股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.51万户。从股价来看，2025年12月31日至2026年3月31日，科源制药区间涨幅为21.23%，在此期间股东户数减少1740.0户，减幅为16.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852488","title":"图解科源制药一季报：第一季度单季净利润同比增长30.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852488","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852488?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:47","pubTimestamp":1776970038,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药2026年一季报显示，一季度公司主营收入1.61亿元，同比上升45.05%；归母净利润3007.34万元，同比上升30.27%；扣非净利润2842.69万元，同比上升50.17%；负债率22.19%，投资收益60.0万元，财务费用19.02万元，毛利率57.6%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400006916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628243811","title":"股市必读：科源制药年报 - 第四季度单季净利润同比下降171.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628243811","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628243811?lang=zh_cn&edition=full","pubTime":"2026-04-17 02:14","pubTimestamp":1776363252,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动截至2026年3月31日公司股东户数为8878.0户，较12月31日减少1740.0户，减幅为16.39%。业绩披露要点财务报告科源制药2025年实现主营收入3.98亿元，同比下降14.12%；归母净利润1655.3万元，同比下降72.62%；扣非净利润2097.38万元，同比下降53.08%。2025年第四季度单季度主营收入9553.98万元，同比下降28.08%；单季度归母净利润-1491.77万元，同比下降171.84%；单季度扣非净利润-167.29万元，同比下降109.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700003177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627238089","title":"科源制药（301281）披露使用部分闲置募集资金及自有资金进行现金管理的公告，4月15日股价上涨2.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627238089","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627238089?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:20","pubTimestamp":1776262827,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，科源制药报收于38.99元，较前一交易日上涨2.77%，最新总市值为42.22亿元。公告显示，公司于2026年4月14日召开第四届董事会第二十一次会议，审议通过使用部分闲置募集资金及自有资金进行现金管理的议案。公司拟使用不超过28,000万元的闲置募集资金和不超过5,000万元的自有资金，投资安全性高、流动性好、保本型短期理财产品或结构性存款，有效期自2025年年度股东会审议通过之日起12个月内，资金可循环滚动使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500043129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627281323","title":"科源制药(301281.SZ)发布2025年度业绩，归母净利润1655.3万元，下降72.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627281323","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627281323?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:54","pubTimestamp":1776254090,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科源制药(301281.SZ)发布2025年年度报告，该公司营业收入为3.98亿元，同比减少14.12%。归属于上市公司股东的净利润为1655.3万元，同比减少72.62%。归属于上市公司股东的扣除非经常性损益的净利润为2097.38万元，同比减少53.08%。基本每股收益为0.15元。此外，拟向全体股东每10股派发现金红利0.5元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"科源制药(301281.SZ)发布2025年度业绩，归母净利润1655.3万元，下降72.62%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627548730","title":"科源制药：力诺制药与江苏赛邦药业有限公司诉讼案件目前已进入二审阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627548730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627548730?lang=zh_cn&edition=full","pubTime":"2026-04-13 15:00","pubTimestamp":1776063639,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)04月12日在投资者关系平台上答复投资者关心的问题。投资者提问：公司现在和赛邦的进展如何，未来如何拓展渠道？科源制药回复：尊敬的投资者您好，公司全资子公司力诺制药与江苏赛邦药业有限公司诉讼案件目前已进入二审阶段，力诺制药将积极维护自身合法权益。如有相关进展，将会根据监管规则进行公告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300013067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","01477","BK1191","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625868988","title":"科源制药（301281）210万股限售股将于4月7日解禁，占总股本1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625868988","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625868988?lang=zh_cn&edition=full","pubTime":"2026-04-07 08:01","pubTimestamp":1775520065,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，科源制药于4月7日将有210.0万股限售股份解禁，为公司首发原股东限售股份，占公司总股本1.94%。本次解禁后，公司还有3733.8万股限售股份，占总股本34.48%。科源制药主营业务：化学原料药及其制剂产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700003281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624668009","title":"科源制药（301281）披露首次公开发行前部分限售股解禁并上市流通提示性公告，4月3日股价下跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668009","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668009?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:18","pubTimestamp":1775225901,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，科源制药报收于34.06元，较前一交易日下跌5.13%，最新总市值为36.88亿元。该股当日开盘35.67元，最高36.12元，最低33.85元，成交额达1.29亿元，换手率为5.46%。公司于近日披露《关于首次公开发行前部分限售股解禁并上市流通的提示性公告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622860304","title":"股市必读：科源制药（301281）3月26日收盘跌10.15%，主力净流出1995.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622860304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622860304?lang=zh_cn&edition=full","pubTime":"2026-03-27 01:12","pubTimestamp":1774545132,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，科源制药报收于41.7元，下跌10.15%，换手率9.41%，成交量6.48万手，成交额2.81亿元。交易信息汇总3月26日科源制药收盘报41.7元，跌10.15%，当日成交648.21万元。该股近5个交易日中有2日跌幅超5%。前10个交易日资金流向显示，主力资金累计净流出428.66万元，股价累计下跌13%；融资余额累计减少1765.98万元，融券余量累计增加0股。资金流向3月26日主力资金净流出1995.85万元；游资资金净流出1129.27万元；散户资金净流入3125.13万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700002810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081721","title":"股市必读：科源制药（301281）3月23日收盘跌10.32%，主力净流出284.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621081721?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:03","pubTimestamp":1774296196,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，科源制药报收于43.9元，下跌10.32%，换手率10.02%，成交量6.9万手，成交额3.19亿元。当日关注点来自交易信息汇总：科源制药3月23日收盘报43.9元，跌10.32%，主力资金净流出284.85万元，散户资金净流入1929.56万元。来自交易信息汇总：该股已连续2日下跌，前10个交易日主力资金累计净流入5236.93万元，股价累计上涨4.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619619674","title":"科源制药（301281）披露控股股东部分股份解除质押及再质押公告，3月16日股价上涨1.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619619674","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619619674?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:20","pubTimestamp":1773670833,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，科源制药报收于50.45元，较前一交易日上涨1.69%，最新总市值为54.63亿元。该股当日开盘49.33元，最高50.95元，最低47.71元，成交额达1.91亿元，换手率为5.6%。公司于近日披露《关于控股股东部分股份解除质押及再质押的公告》。本次质押为力诺投资为力诺集团融资提供的质押担保，不涉及上市公司生产经营，不构成业绩补偿义务。截至公告日，力诺投资累计质押股份数量为29,340,000股，占其所持股份比例77.61%，占公司总股本比例27.09%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600036672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177670331","title":"科源制药股东拟减持不超过3%股份，减持计划为期三个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1177670331","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177670331?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:21","pubTimestamp":1773656468,"startTime":"0","endTime":"0","summary":"科源制药（301281）近日披露，公司一名股东计划在未来三个月内减持其所持有的公司股份，减持比例最高不超过公司总股本的3%。\n此次减持计划若按上限实施，可能对公司的股权结构产生一定影响。根据相关规定，股东减持需遵守信息披露要求，公司已及时对外公告该事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619256451","title":"科源制药最新公告：股东济南鼎佑拟减持不超3.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619256451","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619256451?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:20","pubTimestamp":1773656424,"startTime":"0","endTime":"0","summary":"科源制药(301281.SZ)公告称，股东济南鼎佑健康产业投资合伙企业（有限合伙）计划以集中竞价及大宗交易方式减持公司股份不超过324.87万股（不超过公司总股本的3.00%）；减持原因为经营计划需求；集中竞价减持期间为公告披露之日起十五个交易日后的三个月内，大宗交易减持期间为公告披露之日起三个交易日后的三个月内。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600028181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619158291","title":"科源制药（301281）披露全资子公司银行账户部分金额解除冻结的公告，3月13日股价上涨3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619158291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619158291?lang=zh_cn&edition=full","pubTime":"2026-03-13 22:30","pubTimestamp":1773412244,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，科源制药报收于49.61元，较前一交易日上涨3.46%，最新总市值为53.72亿元。公司于近日披露《关于全资子公司银行账户部分金额解除冻结的公告》。公告显示，山东科源制药股份有限公司全资子公司山东力诺制药有限公司因与江苏赛邦药业有限公司合同纠纷，部分银行账户此前被冻结。2026年3月12日，力诺制药获悉其中一个银行账户部分金额已解除冻结，中国邮政储蓄银行账户解除冻结金额为40,760,000.00元，未解除冻结金额为16,240,000.00元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300041753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281","161121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617064865","title":"科源制药业绩“变脸”再陷困局：诉讼赔偿、战略摇摆与资金链隐忧并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2617064865","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617064865?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:49","pubTimestamp":1772765340,"startTime":"0","endTime":"0","summary":"近日，科源制药因一则业绩预告修正公告引发市场广泛关注。表面诱因为一起诉讼赔偿，但背后折射出的，是企业连续三年业绩下滑、战略摇摆、资金链承压等多重困境。科源制药将此认定为资产负债表日后调整事项，计入2025年度营业外支出。 科源制药于2023年4月登陆A股，上市当年即出现净利润下滑15.6%的“变脸”行情。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-03-06/doc-inhpzkwr9249622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613411717","title":"科源制药最新公告：预计2025年净利润同比减少70%-80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613411717","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613411717?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:11","pubTimestamp":1771942285,"startTime":"0","endTime":"0","summary":"科源制药(301281.SZ)发布2025年度业绩预告修正公告，预计2025年归属于上市公司股东的净利润为1,208.97万元–1,813.45万元，比上年同期下降70%–80%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400043833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613711105","title":"2月24日科源制药发布公告，股东减持28.27万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711105","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613711105?lang=zh_cn&edition=full","pubTime":"2026-02-24 21:01","pubTimestamp":1771938062,"startTime":"0","endTime":"0","summary":"证券之星消息，2月24日科源制药发布公告《科源制药:山东科源制药股份有限公司简式权益变动报告书》，其股东问泽鸿于2026年2月10日至2026年2月13日间合计减持28.27万股，占公司目前总股本的0.2611%，变动期间该股股价上涨11.37%，截止2月13日收盘报37.51元。股东增减持详情见下表：根据科源制药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400042539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608889263","title":"股市必读：科源制药（301281）预计2025年全年归属净利润盈利2720.19万元至3929.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889263","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889263?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:52","pubTimestamp":1769975530,"startTime":"0","endTime":"0","summary":"业绩披露要点业绩预告科源制药发布业绩预告，预计2025年全年归属净利润盈利2,720.19万元至3,929.16万元；扣非后净利润预计盈利2,011.71万元至2,905.81万元。公司公告汇总2025年度业绩预告山东科源制药股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为2,720.19万元至3,929.16万元，较上年同期的6,044.87万元下降35%-55%；扣除非经常性损益后的净利润预计为2,011.71万元至2,905.81万元，同比下降35%-55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777565247214,"stockEarnings":[{"period":"1week","weight":-0.0373},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.1771},{"period":"6month","weight":0.19},{"period":"1year","weight":0.2802},{"period":"ytd","weight":0.2932}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东科源制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8878人(较上一季度减少16.39%)","perCapita":"7991股","listingDate":"2023-04-04","address":"山东省济南市商河县经济开发区科源街","registeredCapital":"10829万元","survey":" 山东科源制药股份有限公司的主营业务是化学原料药及其制剂产品的研发、生产和销售。公司的主要产品是格列齐特、盐酸二甲双胍、盐酸罗哌卡因、单硝酸异山梨酯、单硝酸异山梨酯片、单硝酸异山梨酯缓释片、盐酸氟西汀分散片、化工中间体产品。","listedPrice":44.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科源制药(301281)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科源制药(301281)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科源制药,301281,科源制药股票,科源制药股票老虎,科源制药股票老虎国际,科源制药行情,科源制药股票行情,科源制药股价,科源制药股市,科源制药股票价格,科源制药股票交易,科源制药股票购买,科源制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科源制药(301281)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科源制药(301281)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}